PBC(Mayo Clinic Primary Biliary Cholangitis data)

原发性硬化性胆管炎是一种导致肝脏小胆管破坏的自身免疫性疾病。进展缓慢但不可抗拒，最终导致肝硬化和肝功能失代偿。该病至少从 1851 年开始就得到认可，并于 1949 年被命名为“原发性胆汁性肝硬化”。由于肝硬化只是晚期疾病的特征，因此患者权益团体在 2014 年提议将其名称更改为“原发性胆汁性胆管炎”。
该数据来自于 1974 年至 1984 年间在 PBC 进行的 Mayo Clinic 试验。在这十年间，共有 424 名 PBC 患者转诊至 Mayo Clinic，符合药物 D-青霉胺随机安慰剂对照试验的资格标准。数据集中的前 312 例病例参与了随机试验，并且包含大部分完整的数据。额外的 112 例未参加临床试验，但同意记录基本测量结果并进行生存跟踪。其中 6 例在诊断后不久就失访了，因此这里的数据是关于另外 106 例以及 312 名随机参与者的数据。
在 Fleming 和 Harrington 的附录 D 中找到了几乎相同的数据集；这个版本的缺失值更少。

Primary sclerosing cholangitis is an autoimmune disease that causes destruction of the small bile ducts within the liver. It progresses slowly but inexorably, eventually leading to cirrhosis and hepatic decompensation. This condition has been recognized since at least 1851, and was named "primary biliary cirrhosis" in 1949. As cirrhosis is only a feature of advanced disease, patient advocacy groups proposed renaming it "primary biliary cholangitis" in 2014.

The data originate from a Mayo Clinic trial focused on PBC, conducted between 1974 and 1984. Over this decade, a total of 424 patients with PBC were referred to the Mayo Clinic and met the eligibility criteria for the randomized, placebo-controlled trial of the drug D-penicillamine. The first 312 cases in the dataset participated in the randomized trial, with most of their data fully recorded. An additional 112 patients did not enroll in the clinical trial but agreed to have their basic clinical measurements documented and undergo survival follow-up. Six of these patients were lost to follow-up shortly after diagnosis, so the data presented herein pertain to the remaining 106 patients alongside the 312 randomized participants.

An almost identical dataset is available in Appendix D of Fleming and Harrington; this particular version has fewer missing values.

搜集汇总

背景与挑战

背景概述

该数据集是关于原发性胆汁性胆管炎（PBC）的医学研究数据，来源于1974年至1984年间Mayo Clinic的临床试验，共包含418名患者的记录，主要用于疾病进展和生存分析。数据集由法国研究机构于2020年发布，提供了较完整的测量值和较少的缺失值，适用于统计建模和医学研究。